menu
    • menu
    [{"orgOrder":0,"company":"Rion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Purified Exosome-based Therapy","moa":"","graph1":"Podiatry","graph2":"Phase II","graph3":"Rion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"","sponsorNew":"Rion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rion \/ Not Applicable"},{"orgOrder":0,"company":"Rion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Purified Exosome Product","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Rion","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Rion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Rion \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Rion

    Menu

    Rion

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Rion

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Rion

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Purified Exosome Product

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            RION Initiates Phase 1b Study of Purified Exosome Product™ for Knee Osteoarthritis

                            Details : RION's Purified Exosome Product (PEP) is a shelf stable product in a lyophilized powder derived from human platelets that contains stabilized platelet-derived regenerative exosomes.

                            Brand Name : PEP

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            September 10, 2024

                            Lead Product(s) : Purified Exosome Product

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Rion

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Rion

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Purified Exosome-based Therapy

                            Therapeutic Area : Podiatry

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ventus Initiates Clinical Testing of VENT-03, an Orally Administered cGAS Inhibitor

                            Details : Purified Exosome Product, designed to promote cell growth and formation of new blood vessels, while also reducing inflammation and protecting cells, is being investigated for diabetic foot ulcer.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 07, 2024

                            Lead Product(s) : Purified Exosome-based Therapy

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth